| Sketches of Strength, Chapter 2 - Geraldine Ferraro |
|
|
| Written by Dr. Mel | |||||
| Friday, 13 January 2006 | |||||
Page 3 of 3 For now, in 2000, Geraldine travels to Boston. The myeloma cells are growing and treatment is necessary. She is first given steroids which make her restless and uncomfortable. One of the options at that point was to undergo a stem cell bone marrow transplant where high dose chemotherapy is accompanied by the filtering of one’s own stem cells from the marrow and followed by the reinfusion of the stem cells once most of the marrow is destroyed by the chemo. The stem cells then rebuild the marrow, along with the immune system, with the hope that most of the myeloma cells will be destroyed in the process. The treatment is standard for myeloma, but Geraldine was anxious to try something less harsh and something that was new and promising- so she started with relatively low doses of thalidomide. Geraldine was sleeping again. The thalidomide worked, After a year of treatment with thalidomide, she went into total remission with no sign at all of myeloma in her marrow. She says, “There’s nothing wrong with me!” Well, that may not exactly be the case. The thalidomide does have side effects including neuropathy which is the deadening of nerves in hands and feet. Geraldine does have numbness in a leg, and that effects her walking- but not that much. She is on her treadmill for 25 to 30 minutes each day. She, of course, watches her diet, and amazingly, a bone density test has shown that she has the bones of a 30-year old. She still takes medication to protect her bones, and during those treatments, her husband is always by her side. She calls her husband a “mother hen.” Geraldine is being watched closely. The myeloma could always become active once again. There is still no cure for the disease, and to that effort of finding one, she channeled her political instinct and energy. Initially, she did not go public with her diagnosis. This was a personal matter between herself and her family. But in 2001, she was convinced that she would be able to help countless people if she helped raise awareness of the disease, and at the same time, assisted others in raising funds for myeloma research through congress and the private sector. Maybe it was time for Geraldine to contact her former colleagues and see what could be done in acquiring support for a disease that until recently received so little attention. At that time, a bill was being drafted in congress to appropriate $275 million for blood-related cancer research which would include work in leukemia, lymphoma, as well as myeloma. For the first time, Geraldine stepped up to the cameras and announced her diagnosis. The announcement was carried by all the networks, and she went on to push for approval of the blood cancer bill. An advocacy day was set aside for patients to go to Washington and appeal to their congress people. Geraldine made her own appeals in a special hearing which was broadcast nationally. She garnered tremendous attention and support. The bill was passed. Certainly many advocacy groups and several members of congress including Kay Bailey Hutchison of Texas were key forces in the passage of this milestone legislation, but it was Geraldine who provided the spark which captured the attention of a nation. The appropriation included $25 million for cancer education- that portion of the bill was named the Geraldine Ferraro Cancer Education Program. That’s why Geraldine calls her diagnosis a “win.” This has been her greatest campaign. |
|||||
| < Prev | Next > |
|---|
Multiple Myeloma News Update
-

BBC NewsWhat's Ailing Steve Jobs? Medical Opinion Varies
TIME - 2 hours ago
If a patient were losing the proteins through urine, diabetes could be an explanation, but so could other conditions, including multiple myeloma, ...
Video: Steve Jobs Weight Loss Due to Hormone Imbalance AssociatedPress
Wired speculates about Apple CEO Steve Jobs’ urination, defecation ... MacDailyNews
all 2,614 news articles -
Facet Biotech chief business officer ‘terminated’ Silicon Valley ...
Bizjournals.com, NC - 3 hours ago
Among Facet’s assets is the Phase I multiple myeloma drug elotuzumab. Shah’s base salary last year was $325000. With salary, bonus, the value of stock and ... -
27th Annual JP Morgan Healthcare Conference
Business Wire (press release), CA - 11 hours ago
ACE-011 is currently being studied in a Phase 2 trial in multiple myeloma patients with osteolytic bone disease. ACE-011 is being jointly developed by ... -
Health Notes
Buffalo News, United States - 13 hours ago
... Gilda’s Club WNY, 834-2578; multiple myeloma family, 6 pm Thursday, Roswell Park Cancer Institute, preregistration necessary for new members, 834-2578; ... -
Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 ...
Reuters - Jan 5, 2009
... I clinical trial of its oral CK2 protein kinase inhibitor, CX-4945, in patients with advanced solid tumors, Castleman's disease, or multiple myeloma. ... -
Zacks Analyst Blog Highlights:Celgene Corp., Cytori Therapeutics ...
Reuters - Jan 5, 2009
... dominated by Celgene with complementary Vidaza and Revlimid, although Revlimid and Thalomid face tough competition in the multiple myeloma (MM) market. ... -
Mozobil approved for non-Hodgkin’s lymphoma and multiple myeloma
Prescribing Reference, New York - Dec 18, 2008
... to the bloodstream for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM). ... -
Multiple Myeloma Research Foundation Executive Director and Chief ...
MarketWatch - Dec 17, 2008
ADVISORY, Dec 17, 2008 (GlobeNewswire via COMTEX) -- What: Scott Santarella, Executive Director and COO of the Multiple Myeloma Research Foundation, ...
Multiple Myeloma Research Foundation Executive Director and Chief ... MSNBC
all 11 news articles












